Statement of Changes in Beneficial Ownership (4)
December 11 2019 - 4:45PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Siu Christine |
2. Issuer Name and Ticker or Trading Symbol
Eidos Therapeutics, Inc.
[
EIDX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CFO and Secretary |
(Last)
(First)
(Middle)
C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2000 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/9/2019 |
(Street)
SAN FRANCISCO, CA 94104
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 12/9/2019 | | M | | 10000 | A | $0.59 | 46470 | D | |
Common Stock | 12/9/2019 | | S | | 9099 | D | $59.6185 (1) | 37371 | D | |
Common Stock | 12/9/2019 | | S | | 901 | D | $60.0456 (2) | 36470 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | $0.59 | 12/9/2019 | | M | | | 10000 | (3) | 12/21/2027 | Common Stock | 10000 | $0.00 | 152191 | D | |
Explanation of Responses: |
(1) | Represents the weighted average sale price of the shares sold from $59.00 to $59.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 and 2. |
(2) | Represents the weighted average sale price of the shares sold from $60.01 to $60.115 per share. |
(3) | The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Siu Christine C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO, CA 94104 |
|
| CFO and Secretary |
|
Signatures
|
/s/ Franco Valle, as Attorney-in-Fact | | 12/11/2019 |
**Signature of Reporting Person | Date |
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Apr 2023 to Apr 2024